|Researchers at Purdue University have developed pH-dependent fluorogenic amyloid-beta reporters for the study of Alzheimer's disease (AD). Microglial phagocytosis of amyloid-beta peptides is a critical step in the regulation of brain homeostasis during the initiation and progression of AD. Unlike common methods to study this phenomenon, this technology is specific for amyloid-beta and functions in live cells. The reporter, an isoform of human amyloid-beta tagged with a pH-dependent fluorogenic moiety, fluoresces only upon phagocytosis in the acidic intracellular phagosomes. It clearly differentiates between phagocytic and non-phagocytic cells within live human and nonhuman microglial cells. This technology promises to aid in the discovery of new therapeutics for AD.
-Facilitates live cell tracking of microglial phagocytosis
-Differentiates between phagocytic and non-phagocytic microglial cells
-Development of Alzheimer's Therapeutics
Publication: Monitoring phagocytic uptake of amyloid β into glial cell lysosomes in real time.
Mar 27, 2020
Mar 29, 2019
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486